Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). (April 2017) - Savona, M.R.; Garcia-Manero, G.; Roboz, G.J.; Walsh, K.J.; Kropf, P.L.; Issa, J.P.; O'Connell, C.L.; Tibes, R.; Yee, K.W.L.; Stock, W.; Lunin, S.; Berdeja, J.G.; et al.